Wally Rapattoni

7PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 19, 2024
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.

Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury

|Oct 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

Abhinav Sharma, Pedro Marques, Brendon L Neuen

|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.

Vikas S Sridhar, Brendon L Neuen, Robert A Fletcher

|Mar 28, 2023
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.

Tae Won Yi, Michelle M Y Wong, Brendon L Neuen

|Mar 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.

Michael A Tsoukas, Vincent Woo, Sheldon W Tobe

|Dec 15, 2020
A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate 2 in Ontario, Canada.

Wally Rapattoni, David Zante, Marko Tomas

Pageof 2

Frequent Collaborators

5 joint publications

Brendon L Neuen

5 joint publications

Clare Arnott

4 joint publications

Adeera Levin

2 joint publications

Harpreet S Bajaj